All In Biotech

Drug Trial Radar · NCT01955720

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers

Last checked: Nov 20, 2026Latest source record: Feb 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Sep 2013

Primary completion

May 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate safety, tolerability, PK and PD of BI 655075 and to establish the BI 655075 dose(s) effective to reverse prolongation of blood coagulation time by dabigatran

Conditions

  • Hemorrhage

Interventions

  • BI 655075Drug

  • BI 655075Drug

  • PlaceboDrug

  • BI 655075Drug

  • PlaceboDrug

  • PlaceboDrug

  • PlaceboDrug

  • BI 655075Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reversal of Dabigatran-induced Prolongation of Blood Coagulation TimeTime frame: End of last infusion and 10 minutes after completion of last infusion of BI 655075
  2. The Percentage of Subjects With Drug-related Adverse EventsTime frame: From baseline up to the start of follow-up period (from Day 1 to Day 35)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1321.2.1 Boehringer Ingelheim Investigational Site

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.